Outcome of HCV genotype 1 treatment in HIV-coinfected patients with chronic kidney disease.
Chronic renal insufficiency is a barrier for the treatment of hepatitis C virus (HCV), and yet virus clearance is desirable prior to kidney transplantation. Several reports document success of kidney transplantation in the setting of HIV infection. We analyzed the treatment outcome of patients with HIV and HCV genotype 1 infections and chronic kidney disease, who received pegylated interferon with or without ribavirin in our center. Of the 7 patients, 2 achieved sustained virological response. None of the responders had end-stage renal disease, suggesting that HCV treatment is most likely to be successful in earlier stages of renal disease.
Department of Internal Medicine, Section on Infectious Diseases, Wake Forest Baptist Medical Center, Winston Salem, NC 27157, USA.
Ana Paula
AP
Oppenheimer
James
J
Johnson
Marina
M
Núñez
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications*; D006454:Hemoglobins / Q000032:analysis; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D012254:Ribavirin / Q000627:therapeutic use; D019562:Viral Load
D000998:Antiviral Agents; D006454:Hemoglobins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a